Bibliographic Details
| Title: |
Long-Term Treatment with Ibrutinib in Chronic Lymphocytic Leukemia Patients Normalizes CD3+and CD8+T Cells and Immune Checkpoints Expression but Gradually Leads to CD4+T-Cell Depletion |
| Authors: |
Palma, Marzia, Heimersson, Kia, Näsman-Glaser, Barbro, Mellstedt, Håkan, Österborg, Anders |
| Source: |
Blood; December 2017, Vol. 130 Issue: 1, Number 1 Supplement 1 p4322-4322, 1p |
| Abstract: |
In this study, we analyzed the changes in the peripheral blood mononuclear cells (PBMC) in symptomatic, relapsed or refractory chronic lymphocytic leukemia (CLL) patients (pts) during long-term treatment with the Bruton's tyrosine kinase inhibitor ibrutinib. Peripheral blood (PB) samples were collected before start of treatment with ibrutinib (420 mg/day p.o.) and at week (wk) 4, 10, 16, 22 and at 8, 12 and 24 months (mo) of treatment. Flow-cytometry analyses of PBMC included CLL cells, Natural Killer (NK) cells, T-cell memory subsets, helper subpopulations (Ths) and regulatory T cells (Tregs). |
| Database: |
Supplemental Index |
